Mobile

A 52-week, multi-center, randomized, double-blind, placebo-controlled, time-lagged, parallel group study in patients with mild to moderate Alzheimer's Disease (AD) to investigate the safety, tolerabil...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-000048-10

A 52-week, multi-center, randomized, double-blind, placebo-controlled, time-lagged, parallel group study in patients with mild to moderate Alzheimer's Disease (AD) to investigate the safety, tolerability and Abeta-specific antibody response following three subcutaneous injections of CAD106

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate safety and tolerabiltiy of repeated subcutaneous injections of CAD106 in patients with mild to moderate Alzheimer's disease. To determine time-course and decline, and isotype switch from IgM to Ig Gof the Abeta-specific antibody response in serum, using the Enzyme inked Immunosorbent Assay (ELISA), following rpeated subcutaneous injections of CAD106 or placebo

Critère d'inclusion

  • Alzheimer's disease

Liens